Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 11/20 | 1.00 |
| ▸ | PRKCI | P41743 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | CASP7 | P55210 | 1/20 | 0.55 |
| ▸ | MPI | P34949 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20635749 | 0.93 | PRKCZ (0.87) | PRKCZPRKCIALDH1A1HSD17B10HPGD | |
| SCHEMBL13837635 | 0.85 | PRKCZ (1.00) | PRKCZPRKCIALDH1A1HSD17B10HPGD | |
| SCHEMBL13837726 | 0.84 | PRKCZ (1.00) | PRKCZPRKCIALDH1A1HSD17B10HPGD | |
| SCHEMBL13837694 | 0.82 | PRKCZ (0.69) | PRKCZPRKCIALDH1A1HSD17B10HPGD | |
| SCHEMBL20636242 | 0.82 | PRKCZ (0.69) | PRKCZPRKCIALDH1A1HSD17B10HPGD | |
| SCHEMBL2369127 | 0.82 | PRKCZ (0.69) | PRKCZPRKCIALDH1A1HSD17B10HPGD | |
| SCHEMBL20635613 | 0.81 | PRKCZ (0.68) | PRKCZPRKCIALDH1A1HSD17B10HPGD | |
| SCHEMBL3384989 | 0.81 | PRKCZ (0.74) | PRKCZPRKCIALDH1A1HSD17B10HPGD | |
| SCHEMBL14123517 | 0.80 | PRKCZ (0.73) | PRKCZPRKCIALDH1A1HSD17B10HPGD | |
| SCHEMBL7850695 | 0.80 | PRKCZ (0.66) | PRKCZPRKCIALDH1A1HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889672-B2 | Compounds, formulations, and methods of protein kinase C inhibition | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889672-B2 | Compounds, formulations, and methods of protein kinase C inhibition | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120302561-A1 | Compounds, Formulations, and Methods of Protein Kinase C Inhibition | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302561-A1 | Compounds, Formulations, and Methods of Protein Kinase C Inhibition | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-11-29 | — | — | US | disclosed |
| WO-2012149452-A1 | COMPOUNDS, FORMULATIONS, AND METHODS OF PROTEIN KINASE C INHIBITION | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-11-01 | — | — | WO | disclosed |
| EP-1641803-B3 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2010-12-08 | — | — | EP | disclosed |
| EP-1641803-B1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2009-03-18 | — | — | EP | disclosed |
| EP-1641803-A1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Xention Discovery Limited (GB) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005033102-A2 | THIOPHENE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMPHORA DISCOVERY CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2004111057-A1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION DISCOVERY LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302561-A1 | Compounds, Formulations, and Methods of Protein Kinase C Inhibition | PRKCA, PRKCH, PRKCI | PRKCZ 5/4885PRKCI 3/4885ALDH1A1 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.